Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/45100 
Autor:innen: 
Erscheinungsjahr: 
2008
Schriftenreihe/Nr.: 
WIDER Research Paper No. 2008/36
Verlag: 
The United Nations University World Institute for Development Economics Research (UNU-WIDER), Helsinki
Zusammenfassung: 
A comparative study is undertaken that explores Chinese and Indian pharmaceutical industries under different patent regimes. It is found that relative to India, which had implemented process patent until 2005, China with a product patent regime since 1993 suffers from both lower drug accessibility and availability (the latter is a missing parameter in the literature). Also, China lags behind in both lower R&D investment and patents filed by Chinese nationals. Based on these findings and associated legal interpretation, we conclude that higher patent protection in China generates negative impacts on the pharmaceutical industries. Thus, governments should utilize TRIPS flexibilities and other regimes like price control to offset the anticompetitive effect in designing patent policies.
Schlagwörter: 
product patent
process patent
TRIPS
pharmaceutical industries
China
India
JEL: 
O34
L65
F14
ISBN: 
978-92-9230-082-1
Dokumentart: 
Working Paper

Datei(en):
Datei
Größe
166.11 kB





Publikationen in EconStor sind urheberrechtlich geschützt.